A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

This early-phase study tests REC-1245, a new investigational drug designed to block a protein called RBM39 involved in cancer cell growth, in adults with advanced solid tumors or certain lymphomas that have stopped responding to standard treatments. This is a dose-finding and safety study. **You may be eligible if...** - You are 18 or older - You have a confirmed diagnosis of an advanced solid tumor or relapsed/refractory lymphoma included in this study - Your cancer has progressed on or after at least one prior standard treatment - Your overall health and organ function meet the study's requirements **You may NOT be eligible if...** - You have active uncontrolled brain metastases - You have had certain prior treatments that would affect safety - You have significant heart, liver, or kidney problems - You are pregnant or breastfeeding - You have conditions that interfere with drug absorption (e.g., major GI issues) Talk to your doctor to see if this trial is right for you.